The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recently held a meeting from February 23-26, 2026, and the outcomes are truly groundbreaking! A total of 12 new medicines were recommended for approval, offering hope and potential life-changing treatments to patients across Europe.
Let's dive into the details and explore the impact of these recommendations.
First up, we have mCombriax, a game-changer in the fight against COVID-19 and seasonal influenza. This combined messenger RNA vaccine is a significant step forward, especially for individuals aged 50 and above. With over 280 million COVID-19 cases reported in Europe as of February 1, 2026, and up to 50 million symptomatic cases of seasonal flu each year, mCombriax could be a powerful tool in our public health arsenal.
But here's where it gets controversial... Ojemda, a new oral therapy for paediatric low-grade glioma, a non-cancerous brain tumour, was recommended for conditional marketing authorisation. While surgery and chemotherapy are current treatment options, Ojemda offers a once-weekly oral treatment with potentially fewer side effects. This could be a game-changer for young patients and their families, but what are your thoughts on the potential risks and benefits of such a treatment?
Moving on, the CHMP adopted positive opinions for several other medicines. Onerji was recommended for the treatment of advanced Parkinson's disease, a progressive nervous system disorder. Palsonify received a positive nod for acromegaly, a rare hormonal disorder usually affecting middle-aged adults. Rhapsido was approved for chronic spontaneous urticaria, a long-term itchy rash, and Xolremdi for WHIM syndrome, an ultra-rare hereditary condition impacting the immune system.
And this is the part most people miss... the CHMP also recommended six biosimilar medicines for various conditions, including diabetes, rheumatoid arthritis, and breast cancer. These biosimilars offer similar effectiveness to their reference medicines but at a potentially lower cost, making treatment more accessible.
Additionally, the committee adopted a positive opinion for Acoziborole Winthrop, a single-dose oral treatment for human African trypanosomiasis (sleeping sickness). This medicine simplifies treatment and is intended for use outside the EU, showcasing the EMA's commitment to global health.
However, not all recommendations were positive. The CHMP advised against granting marketing authorisation for Daybu, intended for Rett syndrome, and Iloperidone Vanda Pharmaceuticals for schizophrenia and bipolar disorder. These negative opinions highlight the rigorous evaluation process and the committee's commitment to patient safety.
Furthermore, the committee recommended extending the therapeutic indications for several already authorized medicines, such as Dupixent for chronic spontaneous urticaria in children and Jorveza for eosinophilic oesophagitis in patients aged 2-17 years. These extensions address unmet medical needs and off-label use, ensuring more patients can access appropriate treatments.
Lastly, an application for Zumrad, developed for bladder cancer, was withdrawn. This decision may have been influenced by various factors, and further details can be found in the question-and-answer document.
The agenda and minutes of the February 2026 CHMP meeting are available on the EMA's website, providing transparency and allowing stakeholders to delve deeper into the discussions and decisions.
These recommendations and approvals showcase the EMA's dedication to improving patient care and access to innovative treatments. With 12 new medicines on the horizon, the future looks brighter for patients across Europe. But what are your thoughts on these developments? Do you think these recommendations will have a significant impact on public health? Feel free to share your insights and engage in the discussion below!
